Literature DB >> 31162203

Biphasic Release of the Alarmin High Mobility Group Box 1 Protein Early After Trauma Predicts Poor Clinical Outcome.

William Ottestad1,2, Ingrid N Rognes2, Soeren E Pischke1,3, Tom E Mollnes3,4,5, Ulf Andersson6, Torsten Eken1,2.   

Abstract

OBJECTIVES: The causal role of the prototype alarmin high mobility group box 1 protein in systemic inflammation and remote organ injury after trauma and shock is established in animal models but not in humans. Our aim was therefore to determine high mobility group box 1 protein concentration kinetics with high time resolution during the first hours after trauma in individual patients and investigate the association with outcome.
DESIGN: Prospective single-center observational study.
SETTING: University hospital Level I trauma center. PATIENTS: Convenience recruitment of 136 trauma patients.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Total plasma high mobility group box 1 protein levels were analyzed with enzyme-linked immunosorbent assay in repeated samples. Relationships between predefined predictor variables and outcome were examined in multivariable linear regression models. Ventilator-free days was used as primary outcome measure. Two distinct high mobility group box 1 protein release phases were identified. An initial exponential decay phase with half-life 26 minutes was not correlated with outcome. In contrast, a second high mobility group box 1 protein wave peaking 3-6 hours after trauma in the most severely injured and physiologically deranged patients was consistently the most important predictor of outcome in our multivariable models, rendering all other predictor variables insignificant except for smaller contributions from age and sex, and of admission base excess for maximal creatinine concentration.
CONCLUSIONS: High mobility group box 1 protein was released in two consecutive phases. Only the second high mobility group box 1 protein wave was a significant predictor of outcome. Patients with a high high mobility group box 1 protein concentration between 3 and 6 hours after trauma might hypothetically benefit from high mobility group box 1 protein-specific antagonist therapy.

Entities:  

Year:  2019        PMID: 31162203     DOI: 10.1097/CCM.0000000000003800

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

Authors:  Ulf Andersson; William Ottestad; Kevin J Tracey
Journal:  Mol Med       Date:  2020-05-07       Impact factor: 6.354

2.  Rapid systemic surge of IL-33 after severe human trauma: a prospective observational study.

Authors:  Olav Sundnes; William Ottestad; Guttorm Haraldsen; Torsten Eken; Camilla Schjalm; Peter Lundbäck; Lars la Cour Poulsen; Tom Eirik Mollnes
Journal:  Mol Med       Date:  2021-03-26       Impact factor: 6.354

Review 3.  Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Prevention of Organ Injuries Induced by Traumatic Hemorrhagic Shock.

Authors:  Guillaume Valade; Nicolas Libert; Christophe Martinaud; Eric Vicaut; Sébastien Banzet; Juliette Peltzer
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

4.  HMGB1 concentration measurements in trauma patients: assessment of pre-analytical conditions and sample material.

Authors:  William Ottestad; Ingrid N Rognes; Erlend Skaga; Cassandra Frisvoll; Guttorm Haraldsen; Torsten Eken; Peter Lundbäck
Journal:  Mol Med       Date:  2019-12-31       Impact factor: 6.354

5.  Systemic T Cell Exhaustion Dynamics Is Linked to Early High Mobility Group Box Protein 1 (HMGB1) Driven Hyper-Inflammation in a Polytrauma Rat Model.

Authors:  Preeti J Muire; Martin G Schwacha; Joseph C Wenke
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

6.  HMGB1 Inhibition to Ameliorate Organ Failure and Increase Survival in Trauma.

Authors:  Zhangsheng Yang; Milomir O Simovic; Peter R Edsall; Bin Liu; Tomas S Cancio; Andriy I Batchinsky; Leopoldo C Cancio; Yansong Li
Journal:  Biomolecules       Date:  2022-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.